These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 25613677)
1. The cryptophycins as potent payloads for antibody drug conjugates. Verma VA; Pillow TH; DePalatis L; Li G; Phillips GL; Polson AG; Raab HE; Spencer S; Zheng B Bioorg Med Chem Lett; 2015 Feb; 25(4):864-8. PubMed ID: 25613677 [TBL] [Abstract][Full Text] [Related]
2. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs. Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969 [TBL] [Abstract][Full Text] [Related]
3. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates. Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337 [TBL] [Abstract][Full Text] [Related]
4. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies. Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935 [TBL] [Abstract][Full Text] [Related]
5. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Campos MP; Konecny GE Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302 [TBL] [Abstract][Full Text] [Related]
6. Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting. Weiss C; Figueras E; Borbely AN; Sewald N J Pept Sci; 2017 Jul; 23(7-8):514-531. PubMed ID: 28661555 [TBL] [Abstract][Full Text] [Related]
7. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads. Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791 [TBL] [Abstract][Full Text] [Related]
8. The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Gerber HP; Koehn FE; Abraham RT Nat Prod Rep; 2013 May; 30(5):625-39. PubMed ID: 23525375 [TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugate Payloads; Study of Auristatin Derivatives. Akaiwa M; Dugal-Tessier J; Mendelsohn BA Chem Pharm Bull (Tokyo); 2020; 68(3):201-211. PubMed ID: 32115527 [TBL] [Abstract][Full Text] [Related]
10. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates. Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681 [TBL] [Abstract][Full Text] [Related]
11. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259 [TBL] [Abstract][Full Text] [Related]
12. An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Leong SR; Liang WC; Wu Y; Crocker L; Cheng E; Sampath D; Ohri R; Raab H; Hass PE; Pham T; Firestein R; Li D; Schutten M; Stagg NJ; Ogasawara A; Koppada N; Roth L; Williams SP; Lee BC; Chalouni C; Peng I; DeVoss J; Tremayne J; Polakis P; Polson AG Mol Pharm; 2015 Jun; 12(6):1717-29. PubMed ID: 25853436 [TBL] [Abstract][Full Text] [Related]
14. Natural Product Bis-Intercalator Depsipeptides as a New Class of Payloads for Antibody-Drug Conjugates. Ratnayake AS; Chang LP; Tumey LN; Loganzo F; Chemler JA; Wagenaar M; Musto S; Li F; Janso JE; Ballard TE; Rago B; Steele GL; Ding W; Feng X; Hosselet C; Buklan V; Lucas J; Koehn FE; O'Donnell CJ; Graziani EI Bioconjug Chem; 2019 Jan; 30(1):200-209. PubMed ID: 30543418 [TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugates beyond cytotoxic payloads. Hobson AD Prog Med Chem; 2023; 62():1-59. PubMed ID: 37981349 [TBL] [Abstract][Full Text] [Related]
16. Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy. Yaghoubi S; Karimi MH; Lotfinia M; Gharibi T; Mahi-Birjand M; Kavi E; Hosseini F; Sineh Sepehr K; Khatami M; Bagheri N; Abdollahpour-Alitappeh M J Cell Physiol; 2020 Jan; 235(1):31-64. PubMed ID: 31215038 [TBL] [Abstract][Full Text] [Related]
17. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424 [TBL] [Abstract][Full Text] [Related]
18. The next generation of antibody drug conjugates. Mack F; Ritchie M; Sapra P Semin Oncol; 2014 Oct; 41(5):637-52. PubMed ID: 25440608 [TBL] [Abstract][Full Text] [Related]
19. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads. Chia CSB ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350 [TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates in cancer therapy. Sievers EL; Senter PD Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]